Medicago is pursuing an aggressive discovery and development program that encompasses pandemic and trivalent vaccines, antivirals, antibodies and biologics – including biosimilars and biobetters.


Human papilloma virus (HPV) is the most common sexually transmitted infection (STI) – so common that nearly all sexually active men and women get it at some point in their lives. In 2012 it was estimated that there were 528,000 cases of cervical cancer world-wide, and 266,000 deaths.[WHO 2014]

In most cases, HPV is asymptomatic so it can be passed from one person to another without anyone knowing it. Symptoms can also appear years after exposure, making it difficult to trace.

  • There are many different types of HPV. Some types of HPV, but not all, can cause health problems such as genital warts or cancer.
  • There is no way to know which people who have HPV will develop cancer or other health problems. People with weak immune systems may be less able to fight off HPV and more likely to develop health problems from it, such as people with HIV/AIDS.
  • Vaccination offers effective protection against HPV complications. HPV vaccines are given in three shots over six months; it is important to get all three doses.